Dr. David Howland

• 
  www.als-ny.org/jan14.htm - [Cached Version]
  Published on: 1/14/2005    Last Visited: 3/17/2007  

  Dr. David Howland, principal investigator at Wyeth Research, generated transgenic rats expressing a mutation of G93A in SOD1, and researchers in the Rothstein group at Johns Hopkins, and the Cleveland group at the University of California, San Diego collaborated with Wyeth to characterize this rat model http://www.alsa.org/news/article.cfm?id=291.

• 
  ALS MA Chapter - [Cached Version]
  Published on: 1/26/2005    Last Visited: 2/27/2005  

  Dr. David Howland, principal investigator at Wyeth Research, generated transgenic rats expressing a mutation of G93A in SOD1, and researchers in the Rothstein group at Johns Hopkins, and the Cleveland group at the University of California, San Diego collaborated with Wyeth to characterize this rat model http://www.alsa.org/news/article.cfm?id=291&&CFID=1377719&CFTOKEN=71273851.
  

• 
  Wyeth: News & Announcements - [Cached Version]
  Published on: 2/5/2002    Last Visited: 8/30/2005  

  "The transgenic rat model provides an advantage as scientists seek new therapeutic strategies to treat ALS," says David Howland, principle investigator of the project, Wyeth-Ayerst Research.

Page: